Organon (NYSE:OGN) announced Tuesday the acquisition of regulatory and commercial rights linked to Tofidence, a biosimilar ...

Originally approved by the FDA in September 2023, Biogen's Tofidence became the first tocilizumab biosimilar available in the ...

Purpose: The pharmacology, pharmacokinetics, clinical efficacy, safety, and role of tocilizumab in rheumatoid arthritis (RA) are reviewed. Summary: Tocilizumab is a novel monoclonal antibody that ...

IMPORTANT SAFETY INFORMATION The U.S. prescribing information for TOFIDENCE includes a boxed WARNING for RISK OF SERIOUS INFECTIONS: Patients treated with tocilizumab products, including TOFIDENCE ...

2012;12(3):319-333. The most recent biologic therapy to receive marketing approval, tocilizumab, was evaluated in a 24-week, randomized, placebo-controlled trial (RADIATE) of patients with RA who ...

Regarding myeloma, Burke also shares his experience with myeloma BsAbs, saying, “I follow the drug label, administer the drug ...

In the end, it was the lesser-known repurposed drugs that received far less attention that ended up saving the most lives: ...

The biosimilar of IL-6 inhibitor tocilizumab, called Tyenne (formerly MSB11456), has been approved for the same indications as Roche’s brand, including rheumatoid arthritis, systemic juvenile ...

Reason for decision Not eligible for Health Technology Evaluation guidance Further information Decision makers have concluded that this technology will not progress as a potential technology appraisal ...

I Gedeon Richter Plc. announces today that the European Medicines Agency has accepted Richter’s marketing authorization application (MAA) for ...

In myeloma treatment, acute CRS is a common but treatable AE associated with CAR T-cell therapy and bispecific antibodies, ...